+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Rheumatoid Arthritis: Battlefield At ACR '11 - Next Wave: Innovative Oral Drugs for RA

  • ID: 1948423
  • Report
  • November 2011
  • Region: Global
  • MP Advisors
1 of 2
Competition for the treatment of moderate to severe RA by biologics is growing- from new biologics for novel targets, biosimilars and better biologics. However, there is still ample room for an efficacious affordable oral therapy to tap the mild to moderate RA pts population where biologics have not made a dent. At ACR 2011 (Nov. 5-9, 2011, Chicago), key data on safety and efficacy of PFE’s Tofacitinib (formerly CP-690,550, PhIII, JAK 1/3 inhibitor) will decide the future of oral RA therapeutics. Data focusing on novel targets will assess the opportunity in the growing “TNF-failure” pt population. In this report, we highlight the abstracts related to the novel oral and biologic drugs in the pipeline for the treatment in RA. Over time treatment of RA by oral drugs could oust the injectable anti-TNFs if long term safety and at par efficacy is established. Will Oral RA Drugs Be Successful Like The Anti-TNF Class of Biologics Based Drugs – Is The Key Question In Investors Mind? For more details, please read our meeting preview report released on 1st Nov, 2011 on “Rheumatoid Arthritis: Battlefield at ACR ’11 - Next Wave: Innovative Oral Drugs for RA”.
Note: Product cover images may vary from those shown
2 of 2
- Rheumatoid Arthritis
- RA
- oral
- biologics
- anti-TNF
- SyK
- oral kinase
- tofacitinib
- INCB28050
- TNF-failure
- Disease-modifying anti-rheumatic drugs (DMARDS)
- secukinumab
- ozoralizumab
- VX-509
- fostamatinib
- Oral – Novel Targets
- FMS inhibitor
- apremilast
- Orencia
- Anti-IL-17
Note: Product cover images may vary from those shown